Sonja I. Buschow

Erasmus MC — Netherlands

Immunology and Microbiology · Life Sciences

27h-index3.3kcitations103works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(64), vaccines and immunoinformatics approaches(23), CAR-T cell therapy research(22), Cancer Immunotherapy and Biomarkers(21), Immune Cell Function and Interaction(15)

Publications103 total

Bioorthogonal click chemistry to visualize an immunogenic HLA-A2-restricted hepatitis B virus epitope in human monocyte-derived dendritic cells
The Journal of Immunology·2025Open Access
Author Correction: Geometric deep learning improves generalizability of MHC-bound peptide predictions
Communications Biology·2025Open Access
FRI-059 Identification and characterization of tumor-reactive CD8 and CD4 T cells in hepatocellular carcinoma
Journal of Hepatology·2025
THU-269 Interim results of a phase I/II study to determine the safety, immunogenicity and efficacy of therapeutic hepatitis B virus synthetic long peptide vaccination
Journal of Hepatology·2025
HLA I immunopeptidome of synthetic long peptide pulsed human dendritic cells for therapeutic vaccine design
npj Vaccines·2025· 6 citedOpen Access
Geometric deep learning improves generalizability of MHC-bound peptide predictions
Communications Biology·2024· 10 citedOpen Access
Supplementary Figure 8 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 9 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary methods from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Table 3 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Data from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 2 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 1 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 6 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 5 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 3 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 4 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Table 1 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure 7 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
Supplementary Table 2 from TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer
2024Open Access
page 1 of 6Next →

Frequent Co-authors

Carl G. Figdor(18), I. Jolanda M. de Vries(11), Andrea M. Woltman(9), Robert A. de Man(7), Amy L. Kessler(7), Diahann T. S. L. Jansen(6), Monique T.A. de Beijer(6), Willem Stoorvogel(5), Marco J. Bruno(5), Rachid Bouzid(5), Robbie Luijten(5), Gerty Schreibelt(4), Till S. M. Mathan(4), Dave Sprengers(4), Patrick P.C. Boor(4), Maikel P. Peppelenbosch(4), Stanleyson V. Hato(4), Annemiek B. van Spriel(4), Nadine van Montfoort(4), Luca Beltrame(4)